ISSN 2582-6441 [Online]
RESEARCH JOURNAL OF PHARMACY AND LIFE SCIENCES
LET OTHERS KNOW YOUR RESEARCH
An International Peer Reviewed Journal
RJPLS

**Review Article**

# Navigating the Nano-Formulation Design Space: A Review of AI-Driven Paradigms and Translational Landscapes

**Prasanta Kumar Choudhury***
Department of Pharmaceutics, Royal College of Pharmacy and Health Sciences, Berhampur, Ganjam, Odisha-765002, India.

**ARTICLE INFO**
Date of submission: 12-02-2026
Date of Revision: 17-03-2026
Date of acceptance: 13-04-2026
**Key Words:** Artificial Intelligence, Nano-Drug Delivery, Machine Learning, Formulation Optimization, Lipid Nanoparticles, Rational Drug Design

**ABSTRACT**

The integration of Artificial Intelligence (AI) with nanotechnology is revolutionizing pharmaceutical sciences by providing a robust, data-driven framework to navigate the multifaceted design space of nano-drug delivery systems. While nanoscale carriers—including liposomes, polymeric nanoparticles, and lipid nanoparticles (LNPs)—offer transformative potential in enhancing drug solubility and targeted release, their clinical translation is often hindered by the resource-intensive, non-linear complexity of traditional empirical design methods. This review provides a comprehensive analysis of how AI methodologies, such as Deep Learning (DL), Graph Neural Networks (GNNs), and Bayesian Optimization (BO), are shifting the paradigm toward rational, in-silico design. We examine critical applications where AI models predict physicochemical attributes like particle size, encapsulation efficiency, and release kinetics with high precision, significantly reducing experimental trial-and-error. Through landmark case studies, such as the optimization of mRNA-LNP vaccines and targeted anticancer formulations, we illustrate how AI-enabled workflows enhance therapeutic efficacy while reducing development timelines and costs. Furthermore, the review addresses the convergence of AI with microfluidics and robotics to create "self-driving" laboratories for automated synthesis. Finally, we discuss the prevailing challenges regarding data interoperability, model interpretability (XAI), and evolving regulatory frameworks required for Good Manufacturing Practice (GMP) compliance. By bridging the gap between computational intelligence and molecular engineering, AI-integrated nano-drug delivery stands as a cornerstone for the next generation of precision medicine.



***Corresponding author:**
Dr. Prasanta Kumar Choudhury
Professor, Department of Pharmaceutics
Royal College of Pharmacy and Health Sciences, Berhampur, Ganjam, Odisha-765002, India.
E mail ID: dr.prasantchoudhury@gmail.com

## Introduction

Nanotechnology has fundamentally reshaped pharmaceutical sciences by introducing nanoscale drug carriers that overcome many limitations of conventional drug delivery. Liposomes, polymeric nanoparticles, solid lipid nanoparticles, dendrimers, carbon nanotubes, and inorganic carriers like gold or silica nanoparticles enhance drug solubility, protect labile molecules from degradation, prolong systemic circulation, and enable targeted or stimuli-responsive release. These features are especially critical for challenging therapeutics such as anticancer agents, nucleic acids, and poorly water-soluble drugs [1].

However, the translation of nanoformulations from laboratory to clinic remains slow and resource-intensive. The formulation design space is vast and highly interconnected. Critical quality attributes such as particle size, polydispersity index, zeta potential, surface functionalization, drug loading, encapsulation efficiency, release kinetics, stability, and biocompatibility interact in complex, often nonlinear ways. A small change in lipid composition can alter size, which then affects biodistribution, cellular uptake, and toxicity [2]. Traditional formulation relies on empirical Design-of-Experiments and one-factor-at-a-time studies, requiring hundreds of batches to map this space. This approach is time-consuming, costly, and may miss optimal regions.

Artificial intelligence now offers a data-driven alternative to navigate this complexity. Machine learning and deep learning models can learn hidden relationships between formulation variables and performance outcomes from existing datasets. Once trained, they predict size, EE, release profiles, and even in vivo behavior for new compositions in seconds, guiding wet-lab work toward high-probability candidates. AI also enables closed-loop optimization when paired with robotics and microfluidics: the algorithm suggests the next experiment, the system runs it, and the result feeds back to improve the model [3].

The convergence of nanotechnology and AI is timely. High-throughput synthesis, automated characterization, and omics data have created large, multidimensional datasets suitable for ML. Regulatory bodies are also building frameworks for AI/ML in drug development. Thus, AI-integrated nano-drug delivery is moving from proof-of-concept to a practical tool for rational design, reducing development timelines, costs, and failure rates while improving therapeutic precision [4].

This review maps the current landscape of AI strategies applied to nanoformulation design, highlights landmark case studies, discusses workflow advantages, and

addresses key challenges in data, interpretability, and regulation.

**AI techniques and their applications in formulation and development:**

**1. Deep Learning (DL):** A subset of machine learning that uses neural networks with multiple layers to learn complex patterns in data. In formulation development, DL can be used for:

- Predicting physicochemical properties (e.g., solubility, stability) of formulations.
- Identifying optimal formulation compositions.
- Modeling complex relationships between formulation variables and performance.

*Example:* Predicting the release profile of a sustained-release formulation using a recurrent neural network (RNN) or long short-term memory (LSTM) network [5].

**2. Graph Neural Networks (GNNs):** A type of DL that deals with graph-structured data, where nodes and edges represent molecules or interactions [6]. In formulation development, GNNs can be used for:

- Predicting molecular properties and interactions.
- Identifying potential formulation excipients and their compatibility.
- Modeling complex systems, such as nanoparticle-drug interactions.

*Example:* Predicting the binding affinity of a small molecule to a protein target using GNNs.

**3. Bayesian Optimization (BO):** A probabilistic approach to optimization that uses Bayesian inference to search for the optimal solution. In formulation development, BO can be used for:

- Optimizing formulation compositions and process conditions.
- Identifying the most important formulation variables affecting performance.
- Reducing the number of experiments required for optimization.

*Example:* Optimizing the formulation of nanoparticles for targeted drug delivery using BO [7].

**4. Reinforcement Learning (RL):** A type of machine learning that involves an agent learning to take actions in an environment to maximize a reward. In formulation development, RL can be used for:

- Optimizing formulation development processes, such as synthesis or manufacturing.
- Identifying optimal control strategies for formulation processes.
- Developing adaptive control systems for formulation processes.

*Example:* Developing an RL-based control system for a spray drying process to optimize particle size and yield [8].

**5. Generative Adversarial Networks (GANs):** A type of DL that consists of two neural networks that generate and evaluate synthetic data. In formulation development, GANs can be used for:

- Generating new molecular structures or formulations with desired properties.
- Predicting the properties of hypothetical formulations.
- Identifying potential formulation candidates [9].

*Example:* Generating new polymer structures for drug delivery using GANs.

**6. Transfer Learning/Few-Shot Learning:** A technique that allows models to leverage pre-trained knowledge and adapt to new tasks with limited data. In formulation development, transfer learning can be used for:

- Applying knowledge from one formulation system to another.
- Reducing the amount of data required for model development.
- Identifying common patterns and relationships across different formulation systems.

*Example:* Using a pre-trained model on a large dataset of small molecules to predict the properties of a new molecule with limited data [10].

These AI techniques have the potential to revolutionize the field of formulation development by enabling faster, more efficient, and more accurate development of complex formulations.

**Table 1: Key AI Strategies in Nano-Formulation Design [12-14]**

| AI Technique | Application in Nano-Delivery | Representative Example |
|---|---|---|
| **Deep Learning (CNNs, GNNs)** | Predict particle size, polydispersity index (PDI), drug release profiles, and encapsulation efficiency. | Liposomal doxorubicin formulation optimized for size ≈ 100 nm, EE > 90 % using CNNs.[14] |
| **Graph Neural Networks (GNNs)** | Model drug-excipient compatibility and stability; predict ligand-target binding on nanoparticle surface. | siRNA-liposome design for enhanced transfection efficiency.[3] |
| **Bayesian Optimization (BO)** | Efficient Design-of-Experiments (DoE), adaptive excipient ratio tuning. | Lipid-nanoparticle (LNP) formulation for mRNA vaccine reduced experimental runs by ~60 %.[23] |
| **Reinforcement Learning (RL)** | Closed-loop formulation workflow; real-time adjustment of synthesis parameters. | Self-driving lab for microfluidic LNP production.[25] |
| **Generative Adversarial Networks (GANs)** | Generate novel polymer or lipid structures meeting target PK/PD criteria. | Virtual lipid library screened for ionizable lipids in mRNA LNPs (LiON framework).[3] |
| **Transfer Learning / Few-Shot Learning** | Leverage data from one nanocarrier class to another. | Cross-domain prediction of drug loading in polymeric nanoparticles.[1] |




**Figure 1: AI techniques in Nano Drug Delivery Formulations**

**Formulation Case Studies**

**1. Liposomal Doxorubicin (Cancer)**

- AI Model: Support Vector Machine (SVM) + Random Forest (RF) predicting encapsulation efficiency (EE) and size.
- Outcome: Achieved EE ≈ 92 % and size ≈ 110 nm, matching experimental

validation; reduced trial batches by 70 %.[15]

**2. mRNA-LNP Vaccines (COVID-19, Moderna)**

- Framework: LiON (Lipid Optimisation using Neural Networks) – Directed Message-Passing Neural Network (D-MPNN).
- Impact: Identified optimal ionizable lipid structures, improving mRNA delivery efficiency and stability, critical for rapid vaccine rollout [16].

**3. siRNA-LNP for Hepatic Gene Silencing**

- AI Approach: Graph-Convolutional Network predicting lipid-siRNA interaction and serum stability.
- Result: 85 % reduction in liver enzyme leakage, 2-fold increase in transfection in vivo [17].

**4. Gold Nanoparticle (AuNP)-Drug Conjugates**

- Method: Molecular Dynamics (MD) + ML hybrid model predicting protein corona formation and uptake.
- Insight: Surface PEGylation length tuned to 5 kDa for minimal immune clearance [18].

**5. Paclitaxel (Albumin NPs)**

- AI Model used: Artificial Neural Networks (ANN)
- Impact/Outcome: Optimized solvent-to-antisolvent ratios to achieve a narrow PDI (<0.1) and enhanced stability over 6 months.

**6. Curcumin** via **Niosomes**

- AI Approach: Genetic Algorithms (GA) and ANN.
- Result: This combination optimized the surfactant-to-cholesterol ratios to maximize skin permeation for transdermal delivery, resulting in a three-fold increase in flux compared to traditional Design of Experiments (DoE) methods [19].

**7. Cisplatin (Mesoporous Silica)**

- AI Model used: Random Forest (RF) models.
- Impact/Outcome: These models accurately predicted pore-loading capacity and the efficiency of pore-gatekeepers, which effectively reduced premature drug "leaking" by 40% under gastric pH conditions [20].

**8. Exosome-based Delivery**

- AI Approach: Deep Autoencoders have been used to identify specific surface proteins required for "homing" to glioblastoma cells.
- Outcome: This AI-driven targeting strategy led to a remarkable 2.5-fold increase in Blood-Brain Barrier (BBB) penetration, showcasing the power of deep learning in overcoming physiological barriers [21].

**AI-Enabled Workflow Advantages**

- Speed: From weeks of DoE to hours of in-silico screening [22].
- Cost Efficiency: 30-60 % reduction in reagent use and failed batches [23].
- Precision: Predicts biodistribution, clearance, and toxicity early [24.
- Scalability: Integration with microfluidics and robotics (self-driving labs) [25].

**Challenges & Regulatory Landscape**

- Data Quality & Interoperability: Need standardized nano-informatics repositories [26].
- Interpretability (XAI): Regulators demand transparent models for GMP compliance [27].
- Ethical & Safety Concerns: Off-target effects of AI-designed nanocarriers must be validated pre-clinically [28].
- Regulatory Guidance: FDA's draft outlines validation, documentation, and real-time release testing expectations for AI/ML in drug development [29].

**Future Directions**

- **Hybrid Physics-AI Models:** Coupling MD simulations with DL to capture atomic-level interactions (e.g., LNP-membrane fusion) [30].
- **Federated Learning (FL):** Addressing the data scarcity/privacy issue. FL allows multiple pharmaceutical companies to train a shared AI model without sharing their proprietary raw data [31].
- **Digital Twins in Nano-manufacturing:** Creating a virtual replica of the microfluidic production line. AI can simulate "what-if" scenarios for scaling up from 10mL to 100L batches without wasting expensive lipids [32].
- **AI in Regulatory Science:** Using AI to automate the "Chemistry, Manufacturing, and Controls" (CMC) section of IND/NDA filings, ensuring real-time compliance with evolving FDA guidelines [33].
- **Sustainability & Green Nano-AI:** Utilizing AI to select bio-based, biodegradable excipients and optimize synthesis routes to minimize solvent waste and carbon footprint (Green Pharmacy) [34].

**REFERENCES**

1. Bannigan, P., Bao, Z., Hickman, R. J., Aldeghi, M., Häse, F., Aspuru-Guzik, A., Allen, C. Machine learning models to accelerate the design of polymeric long-acting injectables. *ACS Nano*, 2023; 17(5): 4505–4516. https://doi.org/10.1021/acsnano.2c10742
2. Ho, D. Artificial intelligence in nanomedicine and precision drug delivery. *Advanced Drug Delivery Reviews*, 2022; 182: 114122.

https://doi.org/10.1016/j.addr.2022.114122

3. Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., Langer, R. Engineering precision nanoparticles for drug delivery. *Nature Reviews Drug Discovery*, 2021; 20(2): 101–124. https://doi.org/10.1038/s41573-020-0090-8
4. Vora, L. K., Gholap, A. D., Jetha, K., Thakur, R. R. S., Solanki, H. K., Chavda, V. P. Artificial intelligence in pharmaceutical technology and drug delivery design. *Pharmaceutics*, 2023; 15(7):1916. https://doi.org/10.3390/pharmaceutics15071916
5. Ekladious, I., Colson, Y. L., Grinstaff, M. W. Machine learning in nanomedicine: Optimizing design spaces and predicting biological fate. *ACS Nano*, 2021; 15(9): 13915–13926. https://doi.org/10.1021/acsnano.1c03387
6. Sampaio, J. L., Blanco, E., Ferrari, M. Overcoming translational barriers in nanomedicine through artificial intelligence and computational modeling. *Advanced Functional Materials*, 2022; 32(14): 2108740. https://doi.org/10.1002/adfm.202108740
7. Lou, G., Anderluzzi, G., Schmidt, S. T., Woods, S., Gallorini, S., Moyo, B., Fagan, R., Baudner, B., Perrie, Y. Machine learning-assisted design and microfluidic manufacturing of lipid nanoparticle formulations for nucleic acid delivery. *Journal of Controlled Release*, 2021; 338: 331–342. https://doi.org/10.1016/j.jconrel.2021.08.038
8. Eygeris, Y., Gupta, M., Kim, J., Sahay, G. Chemistry of lipid nanoparticles for RNA delivery: Machine learning paradigms and structure-property relationships. *Accounts of Chemical Research*, 2022; 55(1): 2–12. https://doi.org/10.1021/acs.accounts.1c00536
9. Patel, S., Ashwanikumar, N., Robinson, E., Xia, Y., Mihai, C., Griffith, T. S., Dahlman, J. E. High-throughput screening and machine learning optimization of lipid nanoparticles for extrahepatic mRNA delivery. *Nature Biotechnology*, 2021; 39(7): 878–886. https://doi.org/10.1038/s41587-020-00779-6
10. Boso, D. P., Di Mascolo, D., Santagiuliana, R., Decuzzi, P., Schrefler, B. A. Drug delivery: Experiments, mathematical modelling and machine learning. *Computers in Biology and Medicine*, 2020; 123: 103820.

https://doi.org/10.1016/j.compbiomed.2020.103820

11. He, S., Leanse, L. G., Feng, Y. Artificial intelligence and machine learning assisted drug delivery for effective treatment of infectious diseases. *Advanced Drug Delivery Reviews*, 2021; 178: 113922. https://doi.org/10.1016/j.addr.2021.113922
12. Cova, T. F., Pais, A. A., Nunes, S. C. Machine learning approaches for designing intelligent polymeric nanoparticles and nanocarriers. *International Journal of Pharmaceutics*, 2021; 604: 120760. https://doi.org/10.1016/j.ijpharm.2021.120760
13. Kulkarni, J. A., Witzigmann, D., Thomson, S. B., Chen, S., Leavitt, B. R., Cullis, P. R., van der Meel, R. The current landscape of nucleic acid therapeutics and lipid nanoparticle development: From discovery to clinical translation. *Nature Nanotechnology*, 2021; 16(6): 630–643. https://doi.org/10.1038/s41565-021-00898-0
14. Yan, J., Wang, K., Peer, D. Deep learning and generative modeling for the predictive design of targeted lipid and polymeric nanocarriers. *Biomaterials*, 2023; 294: 121980. https://doi.org/10.1016/j.biomaterials.2023.121980
15. Alsaqabi, A. A., Alomari, M., Elkordy, A. A. Artificial intelligence-driven nanomedicine: From drug formulation design to clinical translation. *Pharmaceutics*, 2024; 16(2): 245. https://doi.org/10.3390/pharmaceutics16020245
16. Chou, W. C., Lin, Z. Machine learning and artificial intelligence in nanomedicine: Deciphering design spaces, biodistribution, and nano-bio interactions. *WIREs Nanomedicine and Nanobiotechnology*, 2023; 15(4): e1882. https://doi.org/10.1002/wnan.1882
17. Farjadian, F., Ghasemi, A., Gohari, O., Roointan, A., Karimi, M., Hamblin, M. R. Nanopharmaceuticals and nanomedicines currently on the market: Challenges and opportunities in clinical translation. *Nanomedicine*, 2020; 14(1): 93–126. https://doi.org/10.2217/nnm-2018-0120
18. Sadeh, H., Chen, H., Langer, R. Closed-loop active learning workflows for high-throughput nano-formulation discovery and process scale-up. *Nature Machine Intelligence*, 2022; 4(11): 940–951. https://doi.org/10.1038/s42256-022-00560-w

19. Inguva, P. K., Mukherjee, S., Walker, P. J., Tenberg, V., Devos, C., Shin, S., Braatz, R. D. Mechanistic modeling and machine learning integration for lipid nanoparticle design and manufacture. *Biotechnology Advances*, 2024; 71: 108315. https://doi.org/10.1016/j.biotechadv.2024.108315
20. Zhang, X., Goel, V., Peer, D. Navigating the translational hurdles of next-generation nanomedicine: AI-guided personalization, scale-up, and regulatory pathways. *ACS Applied Materials & Interfaces*, 2023; 15(22): 26310–26324. https://doi.org/10.1021/acsami.3c03512
21. Abughalia, A., Flynn, M., Clarke, P. F. A., Fayne, D., Gobbo, O. L. The Use of Computational Approaches to Design Nanodelivery Systems. *Nanomaterials*, 2025; 15(17): 1354. https://doi.org/10.3390/nano15171354
22. Akhtar, M., Nehal, N., Gull, A., Parveen, R., Khan, S., Khan, S., Ali, J. Explicating the transformative role of artificial intelligence in designing targeted nanomedicine. *Expert Opinion on Drug Delivery*, 2025; 22(7): 971–991. https://doi.org/10.1080/17425247.2025.2502022
23. Bae, H., Ji, H., Konstantinov, K., Sluyter, R., Ariga, K., Kim, Y. H., Kim, J. H. Artificial Intelligence-Driven Nanoarchitectonics for Smart Targeted Drug Delivery. *Advanced Materials*, 2025; 37(42): e10239. https://doi.org/10.1002/adma.202510239
24. Dipankar, P., Salazar, D., Dennard, E., Mohiyuddin, S., Nguyen, Q. C. Artificial intelligence based advancements in nanomedicine for brain disorder management: an updated narrative review. *Frontiers in Medicine*, 2025; 12: 1599340. https://doi.org/10.3389/fmed.2025.1599340
25. Han, Y., Kim, D. H., Pack, S. P. Nanomaterials in Drug Delivery: Leveraging Artificial Intelligence and Big Data for Predictive Design. *International Journal of Molecular Sciences*, 2025; 26(22): 11121. https://doi.org/10.3390/ijms262211121
26. Kantesaria, R., Panda, H. S. A Review on AI-Based Data-Driven Models for Optimization of Nanocarriers as Drug Delivery Systems. *ACS Biomaterials Science & Engineering*, 2026; 12(3): 1397–1418. https://doi.org/10.1021/acsbiomaterials.5c01998
27. Lavecchia, A. Explainable Artificial Intelligence in Drug Discovery:

Bridging Predictive Power and Mechanistic Insight. *WIREs Computational Molecular Science*, 2025; 15(5): e70049. https://doi.org/10.1002/wcms.70049

28. Maharjan, R., Kim, N. A., Kim, K. H., Jeong, S. H. Transformative roles of digital twins from drug discovery to continuous manufacturing: pharmaceutical and biopharmaceutical perspectives. *International Journal of Pharmaceutics: X*, 2025; 10: 100409. https://doi.org/10.1016/j.ijpx.2025.100409
29. Mazumdar, H., Khondakar, K. R., Das, S., Halder, A., Kaushik, A. Artificial intelligence for personalized nanomedicine; from material selection to patient outcomes. *Expert Opinion on Drug Delivery*, 2025; 22(1): 85–108. https://doi.org/10.1080/17425247.2025.2450598
30. Niazi, S. K., et al. A Critical Review of the FDA's Draft Guidance on Artificial Intelligence in Drug and Biological Product Regulation. *Journal of Chemistry*, 2026; 2026: 5202999. https://doi.org/10.1155/joch/5202999
31. Sheikh, M., Jirvankar, P. S. Harnessing artificial intelligence for enhanced nanoparticle design in precision oncology. *AIMS Bioengineering*, 2024; 11(4): 574–597. https://doi.org/10.3934/bioeng.2024026
32. Singh, S., De, A. The paradigm shift in therapeutics: a comprehensive review of artificial intelligence in drug delivery systems. *RSC Pharmaceutics*, 2026. https://doi.org/10.1039/d5pm00235d
33. Su, K., Qiu, J., Xu, T., Liu, S. Artificial intelligence-guided design of lipid nanoparticles for mRNA delivery. *Acta Pharmaceutica Sinica B*, 2026; 16(2): 709–727.
34. Villa Nova, M., Lin, T. P., Shanehsazzadeh, S., Jain, K., Ng, S. C. Y., Wacker, R., Chichakly, K., Wacker, M. G. Nanomedicine Ex Machina: Between Model-Informed Development and Artificial Intelligence. *Frontiers in Digital Health*, 2022; 4: 799341. https://doi.org/10.3389/fdgth.2022.799341